Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
A Real-world Study of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510407
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- at least 18 years old
- histologically confirmed HCC unsuitable for resection
- lenvatinib as first- or second-line therapy
Exclusion Criteria:
- patients with other primary tumors
- patients who had only one visit record and were lost to follow-up or refused follow-up
- patients with any other factors affecting study data collection
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Lenvatinib combined with Chinese Herbal Medicine
|
Patients were treated with Chinese herbal medicine (CHM).
CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis.
Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians.
The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy outcomes
Time Frame: after 8 weeks of the initiation of Lenvatinib combined with Chinese Herbal Medicine
|
Tumor Response after 8 weeks of treatment according to the modified Response Evaluation Criteria in Solid Tumor (mRECIST)
|
after 8 weeks of the initiation of Lenvatinib combined with Chinese Herbal Medicine
|
|
Survival analysis
Time Frame: 2022/10/01-2023/12/31
|
Kaplan-Meier estimates of overall survival (OS)
|
2022/10/01-2023/12/31
|
|
Survival analysis
Time Frame: 2022/10/01-2023/12/31
|
Kaplan-Meier estimates of progression-free survival (PFS)
|
2022/10/01-2023/12/31
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events assessment
Time Frame: after 8 weeks of the initiation of Lenvatinib combined with Chinese Herbal Medicine
|
Adverse Events (AEs) were assessed following the guidelines of the Common Terminology Criteria for Adverse Events version 4.0.
|
after 8 weeks of the initiation of Lenvatinib combined with Chinese Herbal Medicine
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Suihui Li, postgraduate, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- K-2023-092
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.